Press coverage about Tandem Diabetes Care (NASDAQ:TNDM) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.991300492718 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several research analysts have commented on TNDM shares. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, November 1st. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Piper Jaffray Companies reiterated a “hold” rating and set a $15.00 target price on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Finally, Robert W. Baird reiterated a “hold” rating and set a $3.00 target price on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $11.29.

Tandem Diabetes Care (NASDAQ TNDM) traded up $0.03 during trading hours on Friday, hitting $2.91. The stock had a trading volume of 826,706 shares, compared to its average volume of 1,164,485. Tandem Diabetes Care has a fifty-two week low of $2.15 and a fifty-two week high of $30.00. The company has a market capitalization of $29.45, a P/E ratio of -0.15 and a beta of 0.17. The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, topping the consensus estimate of ($3.74) by $0.65. The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.92 million. During the same quarter last year, the business posted ($0.97) earnings per share. The firm’s revenue for the quarter was up 119.7% compared to the same quarter last year. analysts forecast that Tandem Diabetes Care will post -15.37 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Tandem Diabetes Care (TNDM) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with's FREE daily email newsletter.